Atea Pharmaceuticals, Inc.
AVIRDrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
7wMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
Bemnifosbuvir (BEM)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
Bemnifosbuvir-Ruzasvir
HEPATITIS C VIRUS CHRONIC INFECTION
Bemnifosbuvir-Ruzasvir (BEM/RZR)
HEPATITIS C VIRUS CHRONIC INFECTION
Bemnifosbuvir
Chronic Hepatitis C Virus
AT-527
Hepatitis C
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bemnifosbuvir (BEM) | Phase 3 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection) | - | - |
Bemnifosbuvir-Ruzasvir | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION | - | - |
Bemnifosbuvir-Ruzasvir (BEM/RZR) | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION | - | - |
Bemnifosbuvir | Phase 2 | Chronic Hepatitis C Virus | - | - |
AT-527 | Phase 2 | Hepatitis C | - | - |
HEPATITIS C VIRUS CHRONIC INFECTION
2 drugs in this indication
Chronic Hepatitis C Virus
1 drug in this indication
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
1 drug in this indication
Hepatitis C
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)